Major characteristics of patients, donors, and transplantation procedures in donor/recipient pairs without and with mutated NOD2/CARD15 polymorphisms
. | Patient/donor pairs without mutations (wild type) . | Any patient/donor mutation . |
|---|---|---|
| Patient characteristics | ||
| Age at transplant, y (range) | 45 (16-65) | 42 (17-64) |
| Sex, no. female/no. male | 49/70 | 19/31 |
| Underlying disease | ||
| Acute leukemia, no. (%) | 55 (46) | 23 (46) |
| Myeloproliferative disorder, no. (%) | 27 (23) | 10 (20) |
| Lymphoma/myeloma (%), no. | 37 (31) | 17 (34) |
| Stage at SCT | ||
| Early/intermediate leukemia, no. (%) | 67 (56) | 28 (56) |
| Advanced stage, no. (%) | 52 (44) | 22 (44) |
| Donor characteristics | ||
| HLA-identical sibling, no. (%) | 55 (46) | 23 (46) |
| Matched unrelated donor, no. (%) | 61 (51) | 26 (52) |
| DfRelDonor, no. (%) | 3 (3) | 1 (2) |
| Sex, no. female/no. male | 55/64 | 17/33 |
| Age at donation, y (range) | 41 (16-66) | 40 (17-61) |
| Stem cell source | ||
| Marrow, no. (%) | 28 (24) | 15 (30) |
| Peripheral blood, no. (%) | 91 (76) | 35 (70) |
| Conditioning regimen | ||
| Standard, no. (%) | 70 (59) | 31 (60) |
| RIC, no. (%) | 49 (41) | 21 (40) |
| GvHD prophylaxis | ||
| CsA/MTX, no. (%) | 73 (61) | 32 (64) |
| CsA/MMF, no. (%) | 46 (39) | 18 (36) |
| T-cell depletion | ||
| None, no. (%) | 52 (44) | 18 (36) |
| In vivo; eg, ATG, Campath, no. (%) | 51 (43) | 24 (48) |
| CD34 selection, no. (%) | 16 (13) | 8 (16) |
. | Patient/donor pairs without mutations (wild type) . | Any patient/donor mutation . |
|---|---|---|
| Patient characteristics | ||
| Age at transplant, y (range) | 45 (16-65) | 42 (17-64) |
| Sex, no. female/no. male | 49/70 | 19/31 |
| Underlying disease | ||
| Acute leukemia, no. (%) | 55 (46) | 23 (46) |
| Myeloproliferative disorder, no. (%) | 27 (23) | 10 (20) |
| Lymphoma/myeloma (%), no. | 37 (31) | 17 (34) |
| Stage at SCT | ||
| Early/intermediate leukemia, no. (%) | 67 (56) | 28 (56) |
| Advanced stage, no. (%) | 52 (44) | 22 (44) |
| Donor characteristics | ||
| HLA-identical sibling, no. (%) | 55 (46) | 23 (46) |
| Matched unrelated donor, no. (%) | 61 (51) | 26 (52) |
| DfRelDonor, no. (%) | 3 (3) | 1 (2) |
| Sex, no. female/no. male | 55/64 | 17/33 |
| Age at donation, y (range) | 41 (16-66) | 40 (17-61) |
| Stem cell source | ||
| Marrow, no. (%) | 28 (24) | 15 (30) |
| Peripheral blood, no. (%) | 91 (76) | 35 (70) |
| Conditioning regimen | ||
| Standard, no. (%) | 70 (59) | 31 (60) |
| RIC, no. (%) | 49 (41) | 21 (40) |
| GvHD prophylaxis | ||
| CsA/MTX, no. (%) | 73 (61) | 32 (64) |
| CsA/MMF, no. (%) | 46 (39) | 18 (36) |
| T-cell depletion | ||
| None, no. (%) | 52 (44) | 18 (36) |
| In vivo; eg, ATG, Campath, no. (%) | 51 (43) | 24 (48) |
| CD34 selection, no. (%) | 16 (13) | 8 (16) |
Standard conditioning regimens consisted of 8 Gy to 12 Gy fractionated total body irradiation followed by high-dose cyclophosphamide or classic busulfan/cyclophosphamide; reduced-intensity conditioning (RIC) consisted mainly of fludarabin/BCNU and melphalan regimens. For T-cell depletion, serotherapy with antithymocyte globulin (ATG) or, in a few patients, with Campath, was given in the course of pretransplantation conditioning. There were 24 patients who had been enrolled on a protocol for CD34 selection. All criteria were equally distributed between patients without (n = 119) and with fs(n = 50) mutations of donor or recipient.
DfRelDonor indicates that the donor is a one-HLA-antigen-different relative; CsA, ciclosporin A; MTX, methotrexate; and MMF, myeophenolate-mofetil.